Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671247 | 0.88 | CTSK (0.51) | CTSLCTSBCTSFCTSK | |
| SCHEMBL3687738 | 0.87 | CTSK (0.47) | CTSLCTSBCTSFCTSK | |
| SCHEMBL3681332 | 0.80 | CTSK (0.36) | CTSLCTSBCTSFCTSK | |
| SCHEMBL3680228 | 0.77 | CTSK (0.53) | CTSLCTSBCTSFCTSK | |
| SCHEMBL3681099 | 0.76 | CTSK (0.41) | CTSLCTSBCTSFCTSKHSD11B1 | |
| SCHEMBL3688323 | 0.76 | CTSK (0.45) | CTSLCTSBCTSFCTSK | |
| SCHEMBL3684241 | 0.75 | CTSK (0.44) | CTSKCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2155366 | 0.72 | CTSK (0.45) | CTSLCTSBCTSFCTSK | |
| SCHEMBL5528835 | 0.72 | CTSK (0.43) | CTSLCTSBCTSFCTSKHSD11B1 | |
| SCHEMBL11898023 | 0.72 | CTSK (0.41) | CTSLCTSBCTSFCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694647-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-11-09 | — | — | EP | claimed |
| US-7687524-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2010-03-30 | — | — | US | claimed |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-05-03 | — | — | US | claimed |
| EP-1694647-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2016-11-09 | — | — | EP | disclosed |
| US-7687524-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2010-03-30 | — | — | US | disclosed |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSL 8/4885CTSB 1/4885CTSF 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.